INmune Bio Inc (INMB)
10.13
+0.02
(+0.20%)
USD |
NASDAQ |
May 28, 16:00
10.12
-0.01
(-0.10%)
After-Hours: 20:00
INmune Bio Revenue (Quarterly): 0.014M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.014M |
| December 31, 2023 | 0.028M |
| September 30, 2023 | 0.043M |
| June 30, 2023 | 0.046M |
| March 31, 2023 | 0.038M |
| December 31, 2022 | 0.097M |
| September 30, 2022 | 0.098M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.016M |
| March 31, 2022 | 0.163M |
| December 31, 2021 | 0.163M |
| September 30, 2021 | 0.014M |
| June 30, 2021 | |
| March 31, 2021 | 0.004M |
| December 31, 2020 | 0.011M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.004M
Minimum
Mar 2021
0.163M
Maximum
Dec 2021
0.0565M
Average
0.038M
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 648.83M |
| Sarepta Therapeutics Inc | 413.46M |
| Dare Bioscience Inc | 0.0093M |
| Zevra Therapeutics Inc | 3.425M |
| Kodiak Sciences Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.02M |
| Total Expenses (Quarterly) | 11.03M |
| EPS Diluted (Quarterly) | -0.61 |
| Enterprise Value | 181.85M |
| Profit Margin (Quarterly) | -78.75K% |
| Earnings Yield | -18.95% |
| Normalized Earnings Yield | -18.95 |